What is the incidence of Benign Fasciculation Syndrome (BFS) progressing to Amyotrophic Lateral Sclerosis (ALS) after 6 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Progression of Benign Fasciculation Syndrome to ALS After 6 Years

Based on the available evidence, there are essentially zero documented cases of benign fasciculation syndrome (BFS) progressing to ALS after 6 years of stable symptoms. The prognosis of BFS is favorable regardless of minor EMG abnormalities, and these abnormalities do not necessarily imply progression to ALS 1.

Key Evidence on Long-Term BFS Outcomes

Follow-up Data Beyond 6 Years

  • In a systematic review of 180 BFS patients followed over periods ranging from 8 months to several years, 98.3% had persistent fasciculations but 0% developed motor neuron dysfunction at follow-up 2
  • A dedicated study with median follow-up of 4.7 years (with some patients followed for a median of 6.5 years on repeat EMG) showed no progression to ALS in any patient, including those with chronic neurogenic potentials on initial EMG 1
  • Among the 24 patients with available follow-up data, two-thirds reported symptomatic improvement, and EMG changes remained stable without progression 1

Clinical Significance of the 6-Year Threshold

The 6-year timepoint is particularly meaningful because:

  • BFS patients with abnormal baseline EMG findings (chronic neurogenic potentials) showed stable findings on repeat testing at median 6.5 years, with no development of clinical weakness or ALS 1
  • The systematic literature review confirmed that progression to overt motor neuron disease is described only in specific case reports, not in any systematic follow-up studies 2

Important Clinical Caveats

What Constitutes True BFS

For this benign prognosis to apply, patients must have:

  • Fasciculations as the predominant or sole symptom 1, 2
  • Normal neurological examination without weakness or muscle atrophy 3
  • Normal or only minor chronic neurogenic changes on EMG without active denervation 1

Red Flags That Suggest Alternative Diagnosis

If any of the following develop, the diagnosis is likely not BFS:

  • Clinical weakness or muscle atrophy appearing during follow-up 3
  • Progressive EMG changes showing new active denervation 1
  • Bulbar symptoms (speech or swallowing difficulties) 4

Psychological Factors in BFS

  • Healthcare workers show 5-fold increased odds of BFS, strongly associated with anxiety (60% prevalence) and depression (33.3% prevalence) 3
  • The fear of having ALS itself appears to play an important role in symptom perception and persistence 3

The bottom line: After 6 years of stable BFS without development of weakness, the likelihood of progression to ALS is effectively zero based on all available systematic follow-up data.

References

Research

Clinical progression of benign fasciculation syndrome: a systematic literature review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024

Guideline

Amyotrophic Lateral Sclerosis Classification and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Does benign fasciculation syndrome cause hyperreflexia?
What are the causes of benign fasciculations?
What is the recommended approach to diagnosing benign fasciculation syndrome?
How should I evaluate persistent muscle twitching (fasciculations) when routine laboratory tests are normal?
Can a patient with a history of fasciculations (muscle twitching) that resolved and then recurred 6 years later be at risk for amyotrophic lateral sclerosis (ALS)?
What health risks should I be aware of while on transdermal estrogen therapy (hormone replacement therapy), given my postmenopausal status and family history of hysterectomy?
Why am I experiencing excessive daytime sleepiness and nighttime insomnia while taking 200 mg of progesterone for endometrial protection as a female with an intact uterus?
I'm experiencing daytime sedation on my current hormone replacement therapy regimen of 200 mg micronized progesterone and an estradiol (estrogen) 0.05 mg patch, can my lab results help identify the cause and guide adjustments to my treatment?
Can I cut my 200mg progesterone (a hormone) dose in half, as I've tried administering it vaginally and anally without noticing a difference?
Does vaginal or anal administration of bioidentical hormone replacement therapy (BHRT) reduce tiredness side effects more than oral administration in a woman with a history of taking synthetic hormones?
I have a history of diabetes insipidus (DI) and my lab results show impaired renal concentration with a urine specific gravity below 1.05, accompanied by symptoms of extreme thirst, stomach pain, abdominal pain, hot arms, and cold hands and feet, could these symptoms be related to my condition and what is the difference between hyperthermia and hypothermia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.